NCT06838429Not yet recruiting
PARPi and Ovarian Cancer Survival
Effect of PARP Inhibitors Maintenance Therapy on the Survival Rate of Advanced or Relapsed Epitherlial Ovarian Cancer: an Observational Cohort Study
Source: ClinicalTrials.gov · Last updated 20 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
With the widespread use of PARP inhibitors (PARPi) as maintenance therapy in ovarian cancer, there is still a lack of real-world data from large samples regarding their impact on survival outcomes in advanced and recurrent ovarian cancer. This study aims to conduct a pragmatic cohort study to evaluate the impact of first-line and second-line maintenance treatment with PARPi on survival rates in patients with advanced and recurrent ovarian cancer. The genetic status, different PARPi drugs, and the use of anti-angiogenic inhibitor maintenance therapy or not is used as confounding factors.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 6000 (estimated)
- First submitted
- 17 Feb 2025
- Start date
- Mar 2025
- Primary completion date
- Mar 2026
- Lead sponsor
- Shanghai Gynecologic Oncology Group
- Diseases
- Ovarian cancer
- NCT number
- NCT06838429
What you commit to
- Study type: Observational
- Planned participants: 6000
- From Mar 2025 to the primary completion date, Mar 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Platinum-resistant patients, such as those who had disease progression during chemotherapy or within 6 months after platinum-based chemotherapy.
Other
- Group 1:
- Non-epithelial tumors, borderline tumors, clear cell carcinoma, mucinous carcinoma.
- Missing first-line or follow-up data.
- Group 2:
- Non-epithelial tumors, borderline tumors, clear cell carcinoma, mucinous carcinoma.
- Patients with second relapse.
- Missing second-line or follow-up data.
Who the study is looking for
- Group 1:
- Patients newly diagnosed with stage IIIC or IV primary epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer between December 2013 and December 2024.
- Complete data on first-line treatment and maintenance therapy.
- Availability of follow-up data.
- Group 2:
- Patients with platinum-sensitive first recurrence of any stage of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, diagnosed between December 2013 and December 2024.
- Disease progression occurring at least 6 months after the completion of the last platinum-based chemotherapy regimen.
- Complete data on second-line treatment and maintenance therapy.
- Availability of follow-up data.
Age in the registry: 18 years to 80 years · Sex: Female · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.